Spinraza Add’l Indication Reported to MHLW Panel, Setting Stage for Its Use in All SMA Patients

The Ministry of Health, Labor and Welfare (MHLW) reported its plan to approve an additional indication for Biogen Japan’s spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) to its advisory panel on September 1, paving the way for its approval for...read more